Multimodal Ultrasound for Lymphoma Classification and Treatment Response Prediction
Multimodal Ultrasound-Based Intelligent Classification and Treatment Response Prediction in the Dynamic Evolution of Lymphoma
This prospective, multicenter, observational cohort study aims to evaluate whether multimodal ultrasound can support the noninvasive classification of lymphoma and the early prediction of treatment response.
Adults with newly diagnosed and previously untreated lymphoma will undergo standardized multimodal ultrasound examinations before treatment, after the first treatment cycle, after the fourth treatment cycle, and during follow-up. Ultrasound examinations will include B-mode ultrasound, color Doppler flow imaging, contrast-enhanced ultrasound, super-resolution contrast-enhanced ultrasound, and ultrasound viscoelasticity imaging. Clinical, laboratory, pathological, molecular, treatment, and follow-up information will also be collected.
The study will investigate differences in ultrasound characteristics among lymphoma subtypes, evaluate changes in ultrasound features during treatment, and develop and validate prediction models integrating imaging and clinical information. The main hypothesis is that multimodal ultrasound features and their early treatment-related changes reflect the biological heterogeneity of lymphoma and can improve noninvasive lymphoma classification and early prediction of treatment response.
調査の概要
詳細な説明
This is a prospective, multicenter, observational cohort study of adults with newly diagnosed, previously untreated lymphoma. The study plans to prospectively enroll approximately 2,000 participants across participating centers.
Standardized multimodal ultrasound data will be collected at predefined time points, including before treatment, after the first treatment cycle, after the fourth treatment cycle, and during subsequent follow-up. Imaging modalities include B-mode ultrasound (BUS), color Doppler flow imaging (CDFI), contrast-enhanced ultrasound (CEUS), super-resolution contrast-enhanced ultrasound (SR-CEUS), and ultrasound viscoelasticity imaging (UVE). Clinical and laboratory information, treatment information, pathological diagnosis, immunohistochemical findings, molecular and genetic test results, and follow-up information will also be collected.
The study will first characterize multimodal ultrasound phenotypes across lymphoma categories, including Hodgkin lymphoma and non-Hodgkin lymphoma, indolent and aggressive non-Hodgkin lymphoma, and common pathological subtypes. Longitudinal changes in ultrasound features during treatment will then be evaluated to identify imaging characteristics associated with treatment response.
Using the collected multimodal imaging and clinical data, statistical and machine-learning approaches will be used to develop and validate models for lymphoma classification and early treatment-response prediction. Model development will incorporate imaging features from multiple ultrasound modalities together with relevant clinical information. Model performance will be evaluated using measures of discrimination, calibration, and clinical utility, as appropriate.
The overall objective is to determine whether multimodal ultrasound can provide a noninvasive and repeatable approach for characterizing lymphoma heterogeneity and for identifying treatment response at an earlier stage of therapy.
研究の種類
入学 (推定)
連絡先と場所
研究連絡先
- 名前:Jie Yu, PhD
- 電話番号:01066937110
- メール:jiemi301@163.com
研究場所
-
-
Beijing Municipality
-
Beijing、Beijing Municipality、中国、100853
- 募集
- Chinese PLA General Hospital
-
コンタクト:
- Jie Yu, PhD
- 電話番号:+8601066937110
- メール:jiemi301@163.com
-
主任研究者:
- Jie Yu, PhD
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
Adults with histopathologically confirmed, newly diagnosed, previously untreated lymphoma who present to participating study centers and have at least one lesion suitable for standardized multimodal ultrasound evaluation will be prospectively enrolled.
説明
Inclusion Criteria:
- Age 18 years or older.
- Histopathologically confirmed lymphoma.
- Newly diagnosed and previously untreated, with no prior radiotherapy, chemotherapy, targeted therapy, immunotherapy, or other systemic antitumor treatment before enrollment.
- At least one superficial or otherwise accessible lesion that can be clearly evaluated by ultrasound, such as a cervical, axillary, or inguinal lymph node, with an adequate acoustic window allowing stable acquisition of all five ultrasound modalities.
- Expected survival of more than 3 months.
- No contraindication to the use of ultrasound contrast agents.
- Willingness to undergo multimodal ultrasound examinations before, during, and after treatment and provision of written informed consent.
Exclusion Criteria:
- Target lesion located too deeply or obscured by gas or bone, preventing acquisition of a stable ultrasound imaging plane.
- Known history of hypersensitivity to any component of the ultrasound contrast agent (sulfur hexafluoride microbubbles).
- Known right-to-left cardiac shunt, severe pulmonary hypertension with pulmonary artery pressure greater than 90 mmHg, or uncontrolled hypertension.
- Acute respiratory distress syndrome or severe respiratory insufficiency.
- Unstable angina or acute myocardial infarction within the previous 1 week.
- Pregnancy or breastfeeding.
- Inability, in the investigator's judgment, to cooperate with the complete examination procedure or complete the required follow-up.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:COHORT
- 時間の展望:PROSPECTIVE
コホートと介入
グループ/コホート |
介入・治療 |
|---|---|
|
Newly Diagnosed Untreated Lymphoma Cohort
Adults with pathologically confirmed, newly diagnosed, previously untreated lymphoma who undergo longitudinal multimodal ultrasound examinations and clinical follow-up according to the study protocol. |
Participants undergo standardized multimodal ultrasound examinations including B-mode ultrasound (BUS), color Doppler flow imaging (CDFI), contrast-enhanced ultrasound (CEUS), super-resolution contrast-enhanced ultrasound (SR-CEUS), and ultrasound viscoelasticity imaging (UVE). Examinations are performed at predefined study time points, including before treatment, after the first treatment cycle, after the fourth treatment cycle, and during follow-up. The imaging findings are collected for lymphoma classification and treatment-response prediction. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Area Under the Receiver Operating Characteristic Curve for Differentiating Hodgkin Lymphoma From Non-Hodgkin Lymphoma
時間枠:At the pretreatment baseline assessment, before initiation of antitumor treatment.
|
The area under the receiver operating characteristic curve (AUC) of the multimodal ultrasound model for distinguishing Hodgkin lymphoma from non-Hodgkin lymphoma, using histopathological diagnosis as the reference standard. |
At the pretreatment baseline assessment, before initiation of antitumor treatment.
|
|
Area Under the Receiver Operating Characteristic Curve for Differentiating Indolent From Aggressive Non-Hodgkin Lymphoma
時間枠:At the pretreatment baseline assessment, before initiation of antitumor treatment.
|
The area under the receiver operating characteristic curve (AUC) of the multimodal ultrasound model for distinguishing indolent from aggressive non-Hodgkin lymphoma, using histopathological classification as the reference standard. |
At the pretreatment baseline assessment, before initiation of antitumor treatment.
|
|
Area Under the Receiver Operating Characteristic Curve for Predicting Complete Response After the Fourth Treatment Cycle Using First-Cycle Multimodal Ultrasound
時間枠:After completion of Cycle 1 and Cycle 4 (each cycle is 21 or 28 days, depending on the regimen; approximately 3-4 weeks and 12-16 weeks after treatment initiation, respectively).
|
The area under the receiver operating characteristic curve (AUC) will be used to evaluate the ability of the multimodal ultrasound model to predict complete response (CR) after completion of Cycle 4, using ultrasound features obtained after completion of Cycle 1. Complete response will be assessed by PET/CT or CT according to the study protocol. Each treatment cycle is scheduled to last 21 or 28 days, depending on the prescribed first-line regimen. Assessments are linked to completion of the relevant treatment cycle; the estimated calendar times assume no treatment delays. |
After completion of Cycle 1 and Cycle 4 (each cycle is 21 or 28 days, depending on the regimen; approximately 3-4 weeks and 12-16 weeks after treatment initiation, respectively).
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Sensitivity of the Multimodal Ultrasound Model for Identifying Hodgkin Lymphoma
時間枠:At the pretreatment baseline assessment, before initiation of antitumor treatment.
|
The percentage of participants with histopathologically confirmed Hodgkin lymphoma who are correctly classified as having Hodgkin lymphoma by the multimodal ultrasound model. |
At the pretreatment baseline assessment, before initiation of antitumor treatment.
|
|
Specificity of the Multimodal Ultrasound Model for Identifying Hodgkin Lymphoma
時間枠:At the pretreatment baseline assessment, before initiation of antitumor treatment.
|
The percentage of participants with histopathologically confirmed non-Hodgkin lymphoma who are correctly classified as not having Hodgkin lymphoma by the multimodal ultrasound model. |
At the pretreatment baseline assessment, before initiation of antitumor treatment.
|
|
Sensitivity of the Multimodal Ultrasound Model for Identifying Aggressive Non-Hodgkin Lymphoma
時間枠:At the pretreatment baseline assessment, before initiation of antitumor treatment.
|
The percentage of participants with histopathologically confirmed aggressive non-Hodgkin lymphoma who are correctly classified as having aggressive non-Hodgkin lymphoma by the multimodal ultrasound model. |
At the pretreatment baseline assessment, before initiation of antitumor treatment.
|
|
Specificity of the Multimodal Ultrasound Model for Identifying Aggressive Non-Hodgkin Lymphoma
時間枠:At the pretreatment baseline assessment, before initiation of antitumor treatment.
|
The percentage of participants with histopathologically confirmed indolent non-Hodgkin lymphoma who are correctly classified as not having aggressive non-Hodgkin lymphoma by the multimodal ultrasound model. |
At the pretreatment baseline assessment, before initiation of antitumor treatment.
|
|
Classification Accuracy of the Multimodal Ultrasound Model for Common Lymphoma Subtypes
時間枠:At the pretreatment baseline assessment, before initiation of antitumor treatment.
|
The proportion of participants whose lymphoma subtype is correctly classified by the multimodal ultrasound model, using histopathological diagnosis as the reference standard. |
At the pretreatment baseline assessment, before initiation of antitumor treatment.
|
|
Correlation Between Multimodal Ultrasound Parameters and Tumor Cell Density
時間枠:At the pretreatment baseline assessment, using corresponding ultrasound and pathological data.
|
The association between quantitative multimodal ultrasound parameters and tumor cell density determined by pathological assessment will be evaluated using correlation analysis. |
At the pretreatment baseline assessment, using corresponding ultrasound and pathological data.
|
|
Correlation Between Multimodal Ultrasound Parameters and Pathological Microvessel Density
時間枠:At the pretreatment baseline assessment, using corresponding ultrasound and pathological data.
|
The association between quantitative multimodal ultrasound parameters and microvessel density determined by pathological assessment will be evaluated using correlation analysis. |
At the pretreatment baseline assessment, using corresponding ultrasound and pathological data.
|
|
Concordance Index of the Multimodal Ultrasound Model for Predicting 2-Year Progression-Free Survival
時間枠:From enrollment to the first documented disease progression or death from any cause, whichever occurs first, assessed through 24 months after enrollment.
|
The prognostic performance of the multimodal ultrasound model for predicting 2-year progression-free survival (PFS) will be evaluated using the concordance index (C-index). PFS is defined as the time from the date of initial histopathological diagnosis of lymphoma to the first documented disease progression, relapse, or death from any cause, whichever occurs first. |
From enrollment to the first documented disease progression or death from any cause, whichever occurs first, assessed through 24 months after enrollment.
|
|
Concordance Index of the Multimodal Ultrasound Model for Predicting 2-Year Overall Survival
時間枠:From enrollment to death from any cause, assessed through 24 months after enrollment.
|
The prognostic performance of the multimodal ultrasound model for predicting 2-year overall survival (OS) will be evaluated using the concordance index (C-index). OS is defined as the time from the date of initial histopathological diagnosis of lymphoma to death from any cause. |
From enrollment to death from any cause, assessed through 24 months after enrollment.
|
|
Comparison of Area Under the Receiver Operating Characteristic Curves Between the Multimodal Ultrasound Model and Radiologists
時間枠:At the pretreatment baseline assessment, before initiation of antitumor treatment.
|
The area under the receiver operating characteristic curve (AUC) of the multimodal ultrasound model will be compared with that of radiologists for lymphoma classification, using histopathological diagnosis as the reference standard. |
At the pretreatment baseline assessment, before initiation of antitumor treatment.
|
|
Incidence of Study Ultrasound-Related Adverse Events
時間枠:From enrollment through 24 months after enrollment. Record ultrasound-related adverse events throughout follow-up; observe participants for 15-20 minutes after each contrast-enhanced ultrasound examination.
|
The number and proportion of participants experiencing adverse events related to study ultrasound examinations, particularly contrast-enhanced ultrasound, will be recorded. Contrast-agent-related adverse events will be graded according to the Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. Serious adverse reactions will also be documented. |
From enrollment through 24 months after enrollment. Record ultrasound-related adverse events throughout follow-up; observe participants for 15-20 minutes after each contrast-enhanced ultrasound examination.
|
協力者と研究者
捜査官
- 主任研究者:Jie Yu, PhD、Chinese PLA General Hospital
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
- 2026-532
- U25C2048 (その他の助成金/資金番号:National Natural Science Foundation of China)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。